Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 6/20 | 0.40 |
| ▸ | L3MBTL3 | Q96JM7 | 5/20 | 0.40 |
| ▸ | MBTD1 | Q05BQ5 | 2/20 | 0.36 |
| ▸ | HTR6 | P50406 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | TP53BP1 | Q12888 | 1/20 | 0.31 |
| ▸ | L3MBTL4 | Q8NA19 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL667548 | 1.00 | L3MBTL1 (0.40) | L3MBTL1L3MBTL3MBTD1HTR6ALDH1A1 | |
| SCHEMBL477164 | 1.00 | L3MBTL1 (0.40) | L3MBTL1L3MBTL3MBTD1HTR6ALDH1A1 | |
| SCHEMBL1489870 | 0.98 | L3MBTL3 (0.39) | L3MBTL1L3MBTL3MBTD1HTR6ALDH1A1 | |
| SCHEMBL1489973 | 0.98 | L3MBTL3 (0.39) | L3MBTL1L3MBTL3MBTD1HTR6ALDH1A1 | |
| SCHEMBL1489616 | 0.98 | L3MBTL3 (0.39) | L3MBTL1L3MBTL3MBTD1HTR6ALDH1A1 | |
| SCHEMBL1664709 | 0.95 | — | — | |
| SCHEMBL3933942 | 0.88 | L3MBTL1 (0.39) | L3MBTL1L3MBTL3MBTD1HTR6ALDH1A1 | |
| SCHEMBL174054 | 0.86 | HTR6 (0.42) | L3MBTL1L3MBTL3MBTD1HTR6LMNA | |
| SCHEMBL2008594 | 0.86 | L3MBTL3 (0.38) | L3MBTL1L3MBTL3MBTD1HTR6 | |
| SCHEMBL140623 | 0.84 | L3MBTL1 (0.43) | L3MBTL1L3MBTL3MBTD1HTR6ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 115 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2178879-B1 | 6-CYCLOAMINO-S-(PYRIDAZIN-4-YL)IMIDAZO[1,2-B]-PYRIDAZINE AND DERIVATIVES THEREOF PREPARATION AND THERAPEUTIC APPLICATION THEREOF | SANOFI SA (FR) | 2013-07-03 | — | — | EP | claimed |
| US-8455491-B2 | 6-cycloamino-3-(pyridazin-4-yl)imidazo[1,2-b]pyridazine and derivatives and pharmaceutical compositions comprising the same | SANOFI (FR) | 2013-06-04 | — | — | US | claimed |
| US-20100152157-A1 | 6-CYCLOAMINO-3-(PYRIDAZIN-4-YL)IMIDAZO[1,2-b]-PYRIDAZINE AND DERIVATIVES THEREOF PREPARATION AND THERAPEUTIC APPLICATION THEREOF | SANOFI-AVENTIS (FR) | 2010-06-17 | — | — | US | claimed |
| EP-1828223-A4 | NOVEL BETULIN DERIVATIVES, PREPARATION THEREOF AND USE THEREOF | PANACOS PHARMACEUTICALS INC (US) | 2009-03-11 | — | — | EP | claimed |
| WO-2008057420-A2 | EXTENDED TRITERPENE DERIVATIVES | PANACOS PHARMACEUTICALS, INC. (US) | 2008-05-15 | — | — | WO | claimed |
| EP-1828223-A2 | NOVEL BETULIN DERIVATIVES, PREPARATION THEREOF AND USE THEREOF | Panacos Pharmaceuticals, Inc. (US) | 2007-09-05 | — | — | EP | claimed |
| WO-2006053255-A2 | NOVEL BETULIN DERIVATIVES, PREPARATION THEREOF AND USE THEREOF | PANACOS PHARMACEUTICALS, INC. (US) | 2006-05-18 | — | — | WO | claimed |
| CN-111743901-B | Spray-dried formulations | 普尔莫凯恩股份有限公司 | 2023-09-12 | — | — | CN | disclosed |
| EP-3054937-B1 | SPRAY DRY FORMULATIONS | PULMOKINE INC (US) | 2023-07-26 | — | — | EP | disclosed |
| CN-111743901-A | Spray-dried formulations | 普尔莫凯恩股份有限公司 | 2020-10-09 | — | — | CN | disclosed |
| CN-106132403-B | Spray-dried formulations | 普尔莫凯恩股份有限公司 | 2020-04-28 | — | — | CN | disclosed |
| US-20190248761-A1 | NON-SELECTIVE KINASE INHIBITORS | PULMOKINE INC (US) | 2019-08-15 | — | — | US | disclosed |
| US-10246438-B2 | Non-selective kinase inhibitors | PULMOKINE, INC (US) | 2019-04-02 | — | — | US | disclosed |
| EP-0858452-B1 | THIAZOLE DERIVATIVE AS PROTEIN KINASE C INHIBITORS | OTSUKA PHARMA CO LTD (JP) | 2002-03-13 | — | — | EP | disclosed |
| US-6140330-A | USEFUL AS PROTEIN KINASE INHIBITOR; FOR TREATMENT OF AUTOIMMUNE DISEASES SUCH AS RHEUMATOID ARTHRITIS, SYSTEMIC LUPUS ERYTHEMATOSUS, MULTIPLE SCLEROSIS, PSORIASIS, ETC., VARIOUS ALLERGIC DISEASES SUCH AS CROHN'S DISEASE, ASTHMA | OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) | 2000-10-31 | — | — | US | disclosed |
| EP-0858452-A1 | THIAZOLE DERIVATIVE AS PROTEIN KINASE C INHIBITORS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1998-08-19 | — | — | EP | disclosed |
| WO-1998004536-A1 | THIAZOLE DERIVATIVE AS PROTEIN KINASE C INHIBITORS | OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) | 1998-02-05 | — | — | WO | disclosed |
| US-5358949-A | Carbostyril derivatives and salts thereof and anti-arrhythmic agents containing the carbostyril derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1994-10-25 | — | — | US | disclosed |
| EP-0373531-A1 | Novel pyridobenzoxazine derivative | WAKUNAGA SEIYAKU KABUSHIKI KAISHA (JP) | 1990-06-20 | — | — | EP | disclosed |
| EP-0236140-A2 | Carbostyril derivatives and salts thereof and anti-arrhythmic agents containing the carbostyril derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1987-09-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10246438-B2 | Non-selective kinase inhibitors | ERBB2, KDR, ERBB3 | L3MBTL1 2343/4885L3MBTL3 3092/4885MBTD1 1965/4885 |
| US-20190248761-A1 | NON-SELECTIVE KINASE INHIBITORS | ERBB2, KDR, ERBB3 | L3MBTL1 2343/4885L3MBTL3 3092/4885MBTD1 1965/4885 |
| US-20100152157-A1 | 6-CYCLOAMINO-3-(PYRIDAZIN-4-YL)IMIDAZO[1,2-b]-PYRIDAZINE AND DERIVATIVES THEREOF PREPARATION AND THERAPEUTIC APPLICATION THEREOF | IFNAR1, TLR7, CBR3 | L3MBTL1 775/4885L3MBTL3 347/4885MBTD1 3734/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.